Rivastigmine: An open-label observational study of behavioral symptoms identified as most troubling by caregivers of patients with Alzheimer's disease

Mary L Lilly, Martin R. Farlow

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Behavioral problems exhibited by persons with Alzheimer's disease are distressing for caregivers and are associated with a number of negative outcomes, including increased risk of long-term care placement. Studies of cholinesterase inhibitor therapy for up to 1 year document modest improvements in behavioral symptoms and functional status. Objective. The long-term effects of rivastigmine, a cholinesterase inhibitor, on behavioral symptoms and functional status in a sample of patients with Alzheimer's disease were examined. Design. This is an observational study of behavioral data reported by caregivers for 32 initially mild to moderate Alzheimer's patients participating in an open-label extension of a prospective, randomized study of rivastigmine as a treatment for Alzheimer's disease. Results. Patients followed in the open-label phase of this trial experienced a decline in behavioral symptoms in general and a decline in symptoms identified as most troubling by the caregiver. Conclusion. This study supports the effectiveness of cholinesterase inhibitors, such as rivastigmine, in the long-term management of behavioral symptoms in Alzheimer's patients.

Original languageEnglish (US)
Pages (from-to)293-297
Number of pages5
JournalJournal of the American Psychiatric Nurses Association
Volume11
Issue number5
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

Rivastigmine
Behavioral Symptoms
Caregivers
Observational Studies
Cholinesterase Inhibitors
Alzheimer Disease
Long-Term Care
Prospective Studies
Therapeutics

Keywords

  • Alzheimer's disease
  • Dementia
  • Problem behaviors
  • Rivastigmine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Nursing(all)

Cite this

@article{e8a0742b3bb748a89d247be6f26fac72,
title = "Rivastigmine: An open-label observational study of behavioral symptoms identified as most troubling by caregivers of patients with Alzheimer's disease",
abstract = "Background. Behavioral problems exhibited by persons with Alzheimer's disease are distressing for caregivers and are associated with a number of negative outcomes, including increased risk of long-term care placement. Studies of cholinesterase inhibitor therapy for up to 1 year document modest improvements in behavioral symptoms and functional status. Objective. The long-term effects of rivastigmine, a cholinesterase inhibitor, on behavioral symptoms and functional status in a sample of patients with Alzheimer's disease were examined. Design. This is an observational study of behavioral data reported by caregivers for 32 initially mild to moderate Alzheimer's patients participating in an open-label extension of a prospective, randomized study of rivastigmine as a treatment for Alzheimer's disease. Results. Patients followed in the open-label phase of this trial experienced a decline in behavioral symptoms in general and a decline in symptoms identified as most troubling by the caregiver. Conclusion. This study supports the effectiveness of cholinesterase inhibitors, such as rivastigmine, in the long-term management of behavioral symptoms in Alzheimer's patients.",
keywords = "Alzheimer's disease, Dementia, Problem behaviors, Rivastigmine",
author = "Lilly, {Mary L} and Farlow, {Martin R.}",
year = "2005",
month = "10",
doi = "10.1177/1078390305282210",
language = "English (US)",
volume = "11",
pages = "293--297",
journal = "Journal of the American Psychiatric Nurses Association",
issn = "1078-3903",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Rivastigmine

T2 - An open-label observational study of behavioral symptoms identified as most troubling by caregivers of patients with Alzheimer's disease

AU - Lilly, Mary L

AU - Farlow, Martin R.

PY - 2005/10

Y1 - 2005/10

N2 - Background. Behavioral problems exhibited by persons with Alzheimer's disease are distressing for caregivers and are associated with a number of negative outcomes, including increased risk of long-term care placement. Studies of cholinesterase inhibitor therapy for up to 1 year document modest improvements in behavioral symptoms and functional status. Objective. The long-term effects of rivastigmine, a cholinesterase inhibitor, on behavioral symptoms and functional status in a sample of patients with Alzheimer's disease were examined. Design. This is an observational study of behavioral data reported by caregivers for 32 initially mild to moderate Alzheimer's patients participating in an open-label extension of a prospective, randomized study of rivastigmine as a treatment for Alzheimer's disease. Results. Patients followed in the open-label phase of this trial experienced a decline in behavioral symptoms in general and a decline in symptoms identified as most troubling by the caregiver. Conclusion. This study supports the effectiveness of cholinesterase inhibitors, such as rivastigmine, in the long-term management of behavioral symptoms in Alzheimer's patients.

AB - Background. Behavioral problems exhibited by persons with Alzheimer's disease are distressing for caregivers and are associated with a number of negative outcomes, including increased risk of long-term care placement. Studies of cholinesterase inhibitor therapy for up to 1 year document modest improvements in behavioral symptoms and functional status. Objective. The long-term effects of rivastigmine, a cholinesterase inhibitor, on behavioral symptoms and functional status in a sample of patients with Alzheimer's disease were examined. Design. This is an observational study of behavioral data reported by caregivers for 32 initially mild to moderate Alzheimer's patients participating in an open-label extension of a prospective, randomized study of rivastigmine as a treatment for Alzheimer's disease. Results. Patients followed in the open-label phase of this trial experienced a decline in behavioral symptoms in general and a decline in symptoms identified as most troubling by the caregiver. Conclusion. This study supports the effectiveness of cholinesterase inhibitors, such as rivastigmine, in the long-term management of behavioral symptoms in Alzheimer's patients.

KW - Alzheimer's disease

KW - Dementia

KW - Problem behaviors

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=27744564294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744564294&partnerID=8YFLogxK

U2 - 10.1177/1078390305282210

DO - 10.1177/1078390305282210

M3 - Article

AN - SCOPUS:27744564294

VL - 11

SP - 293

EP - 297

JO - Journal of the American Psychiatric Nurses Association

JF - Journal of the American Psychiatric Nurses Association

SN - 1078-3903

IS - 5

ER -